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Summary : Two originally prepubertal girls su†ering from glycogen storage
disease type Ia and short stature were treated with low-dose diazoxide (3È4.8
mg/kg per day) for 7 and 4 years, respectively. Both showed an impressive
catch-up growth following this treatment. This appeared to be due to prolonga-
tion of normoglycaemia after meals and reduction of fasting lactic acidosis by
diazoxide.
Growth retardation is a well-known complication in patients with glucose-6-phos-
phatase deÐciency (glycogen storage disease (GSD) type Ia ; McKusick 232200)
(Fernandes and Berger 1987). It is almost universal in infancy but responds variably
to di†erent types of therapies for reasons that are not yet clear. Introduction of
uncooked cornstarch during night time as well as nocturnal gastric tube feeding
partially improved height velocity (Wolfsdorf et al 1990 ; Chen et al 1993) but not in
all patients. The use of diazoxide in patients with GSD type Ia was Ðrst described
by Rennert and Mukhopadhyay (1968) for the improvement of glucose homeostasis.
The treatment was of short-term duration because of skin rashes and was later
forgotten. Unaware of this early observation, we started to treat a female patient
with diazoxide in 1987. In this paper, we report as a new Ðnding a catch-up growth
in two prepubertal female patients with GSD type Ia following prolonged treatment
with low doses of diazoxide (3È4.8 mg/kg per day) for 7 and for 4 years, respectively.
Since diazoxide therapy prolongs normoglycaemia in the patients, it signiÐcantly
reduces elevated blood lactate concentrations. We therefore speculate that blood
lactic acidosis is a major cause of growth retardation in GSD type Ia and that
growth retardation may be alleviated by long-term diazoxide treatment.
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Figure 1 (a) Growth chart (Prader et al 1989) of patient 1. Start of diazoxide therapy and
adaptation of dosage for increased weight, on two occasions, are indicated by arrows. A few
months after introduction of diazoxide therapy an impressive catch-up growth started. Bone
age remained retarded throughout the treatment with diazoxide and, as indicated in the(L)
lower part of the chart, there was a delayed pubertal development
CASE REPORTS
The Ðrst patient, a girl, was born as the third child to unrelated parents after a
41-week normal pregnancy, birth weight 3920 g (50thÈ90th centile), length 51 cm
(50thÈ90th centile), head circumference 35 cm (50th centile). At the second day of
life, the child was referred to our hospital because of a transient tachypnoea of the
newborn (TTN) with metabolic acidosis (pH 7.35, 21.3 mmHg, base excesspCO2[10). Lactate measured 9 days later was 2.98 mmol/L. In addition a hepatomegaly
(5.5 cm below costal margin) and a functional systolic murmur were found. Hyper-
insulinism causing hypoglycaemia was excluded. There was no rise in blood glucose
concentrations but an increase in lactate after intravenous glucagon. Diagnosis of
glucose-6-phosphatase deÐciency was established at 4 weeks of age by liver biopsy.
A diet consisting of 6È8 meals per day restricted in galactose and fructose but
enriched in glucose and polyunsaturated fat was initiated. Uncooked cornstarch was
introduced at the age of 3 months (2 g/kg body weight distributed over all meals
initially, later during night time). Oral therapy with was started at 3NaHCO3
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Figure 1 (b) Growth chart (Prader et al 1989) of patient 2. Start of diazoxide therapy is
indicated by an arrow. A few months after introduction of diazoxide therapy an impressive
catch-up growth started. There was a delayed pubertal development, as indicated in the lower
part of the chart, and bone age remained retarded during the Ðrst year of catch-up(L)
growth. Later, growth and bone age were probably a†ected by advancing pubertal develop-
ment
months of age and at 10 months allopurinol was added. This medication has contin-
ued up to the present time.
The patient was seen at regular intervals in our outpatient clinic. She was admit-
ted several times to our hospital because of recurrent urinary tract infections with
poor control of glycaemia. A malformation of the urinary tract could be excluded.
Urinary tract infections subsided after the age of 10 years. Preprandial hyper-
lacticacidaemia was repeatedly measured at 08 :00 to 09 :00 (Table 1). It still persist-
ed when uncooked cornstarch was given during night time.
Initially (according to the Swiss growth charts, Prader et al (1989)), the girl grew
between [0.3 and [1 SDS. After the age of 5 years, the growth gradually dropped
until it was below [2 SDS at 8 years of age (Figure 1a).
At the age of years a trial with diazoxide (initially 4.8 mg/kg per day divided101112
in three doses) was started. The drug was given with the main meals. Following this
treatment a signiÐcant reduction of both blood lactate concentrations and hyperlip-
idaemia was achieved. At the age of and of 15 years respectively, the dosage of13 412
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Figure 2 E†ects of diazoxide (open circles and broken curve) on blood lactate (solid squares
and solid curve) in patient 1. Start of diazoxide therapy is indicated with an arrow. Diazoxide
was given in three divided doses with the main meals. The dosage was adapted for increased
weight on two occasions because the metabolic parameters (lactate and lipids) again became
less favourable. Blood lactate was determined between 08 :00 and 09 :00 after 2 h fasting
diazoxide was adapted for increased weight, because the metabolic parameters
(lactate and lipids) again became less favourable (Figure 2).
Following this observation, we decided to treat another prepubertal Swiss patient
with GSD type Ia. Her growth pattern had followed the curve [0.5 to [1 SDS on
the Swiss growth chart (Prader et al 1989) until 2 years and dropped below [2 SDS
at 3 years of age (Figure 1b). A trial with diazoxide (3.3 mg/kg per day taken in
three doses together with the main meals) was started at years of age. Previous11 412
to treatment bone age was retarded by 4 years according to Greulich and Pyle
(1959). Since this patient lives in Asia, controls were possible only once a year
during vacations in Switzerland. Apart from frequent meals, a special diet was not
followed but she had uncooked cornstarch during the night time.
EFFECTS OF DIAZOXIDE TREATMENT
Shortly after the introduction of diazoxide therapy, lactic acidaemia signiÐcantly
decreased in both patients. Furthermore, after 12 months on treatment an impres-
sive increase in the 1 year height velocity (cm/year) SDS was noted (Figure 3). The
di†erence of height velocities SDS (pretreatment and on treatment) was signiÐcant
(Table 1). Bone age assessed according to the method by Greulich and Pyle (1959)
remained retarded by 2È3 years in the Ðrst patient, and her pubertal development
was still clearly delayed during the Ðrst years of her catch-up growth (Figure 1a). In
the meantime, puberty started. In case 2, delay of bone age had lessened at the time
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of the last clinical control in our outpatient clinic and pubertal development prog-
ressed to maturity. The initial catch-up growth, however, did not occur at the
expense of advance in bone age.
As shown in Table 1, there was a signiÐcant amelioration of HDL-cholesterol and
triglycerides in patient 1, whereas total cholesterol remained elevated. In patient 2,
values of blood lipids remained abnormally high despite diazoxide therapy. There
were no signiÐcant changes of plasma pH and bicarbonate following diazoxide
therapy ; a reduction of negative base excess in both patients was suggested but not
statistically validated.
In both patients, liver size diminished during diazoxide administration. In the Ðrst
patient, liver size before treatment was 12.3^ 0.5 cm below costal margin. After 1
year of therapy, the liver size reduced to 8.0 cm and has remained 8.8^ 1 cm up to
the present time. In the second patient, the liver size before treatment was 13.5 ^ 0.5
cm; during 3 years of treatment it was 11.5^ 0.5 cm. Following treatment with
diazoxide, a signiÐcant weight gain was experienced from initially the 25th to the
97th centile over a period of 7 years in the Ðrst case, and from the 25th to the 50th
centile over a period of 3 years in the second case.
No signiÐcant side-e†ects, such as hypertrichosis, water retention, change in
blood pressure or worsening of hyperuricaemia, were noted in either patient. To
monitor the risk of diazoxide administration producing hyperglycaemic insulino-
penia in the patients, fructosamine and were measured regularly. These para-HbA1c
meters remained normal in both patients.
Figure 3 Growth versus blood lactate (patient 1). Blood lactate (broken curve) was deter-
mined between 08 :00 and 09 :00 after 2 h fasting. Growth data are given in one-year height
velocity standard deviation scores (open circles, solid curve) (Prader et al 1989). Diazoxide
therapy was started at the age of years. The dosage was adapted for increased weight on101112two occasions, because the metabolic parameters (lactate and lipids) again became less
favourable
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In case 1, oral glucose tolerance test (45 g/m2) was performed after 2 h fasting and
administration of 25 mg diazoxide. Blood sugar concentrations prior to the test
were 4.92 mmol/L (norm 4.23^ 0.49) ; at 30 min 9.74 mmol/L (norm 7.4^ 1.3) ; at
60 min 8.01 mmol/L (norm 6.4^ 1.1) ; at 120 min 6.88 mmol/L (norm 5.3^ 0.8) ;
and at 180 min 3.88 mmol/L (norm 4.0^ 0.9), respectively. The corresponding
insulin concentrations were at the mean level for healthy controls : at the beginning
13 mU/L (norm 9.5 ^ 7.1) ; at 30 min 46 mU/L (norm 49 ^ 25.7) ; at 60 min 53
mU/L (norm 47.7 ^ 36.3) ; at 120 min 35 mU/L (norm 31.3 ^ 26) ; and at 180 min 6
mU/L (norm 16.7 ^ 13.5). C-Peptide values remained at the lowest norm through-
out the test. Lactate at the beginning of the test was only slightly elevated (2.73
mmol/L).
DISCUSSION
In GSD type Ia the release of free glucose from glucose 6-phosphate from the liver
into the blood is greatly impaired, although glycogenolysis and glycogenesis are
normal. This results in early hypoglycaema 2È3 h after a meal. Since glycolysis of
glucose 6-phosphate is intact or even intensiÐed under hormonal counterregulation
similar to a fasting state, production of pyruvate and lactate is increased. Lactic
acidosis becomes more severe whenever postabsorptive sources of glucose are
exhausted. The resulting chronic acidosis is usually treated by alkalinization with
oral doses of NaHCO3 .
Chronic metabolic acidosis is an important growth-inhibiting factor as shown by
Challa and colleagues (1993) and in clinical studies by Mehls and colleagues (1992).
A severe lactic acidaemia exceeding 5 mmol/L seems to impair normal growth (Smit
1993). Therefore, short stature and growth retardation are common features of GSD
type Ia, especially in pre- and pubertal patients, although postpubertal catch-up
growth seems possible (Smit 1993).
Therapy with diazoxide was started with the idea of avoiding early and prolonged
hypoglycaemic states between meals as well as to reduce excessive production of
lactate. Diazoxide was introduced for therapy of idiopathic hypoglycaemia in child-
hood (Goodman et al 1968). It was equally successful in preventing hypoglycaemia
in patients a†ected with hypopituitary dwarÐsm (Ventura et al 1983). In 1968,
Rennert and Mukhopadhyay suggested treatment with diazoxide in patients with
GSD type Ia. Only a few other clinicians (Bartolozzi et al 1975 ; Gardoni and Giran-
zani 1978) took up this proposition. All reported an improved glucose, lipid and
acid homeostasis and a marked reduction in hepatomegaly in several patients. In
most patients, however, diazoxide had to be stopped because of various cutaneous
allergic reactions. To our knowledge there are no reports on long-term treatment
with diazoxide in GSD patients, and more speciÐcally e†ects on growth retardation
in GSD Ia.
The mode of action of diazoxide seems to be linked to K`-ATP channel activa-
tion. The resulting hyperpolarization of the membranes decreases insulin release
(Dunne et al 1987 ; Edwards and Weston 1990). Diazoxide is usually given in 3È4
doses at meal times. Its half-life in the body after oral administration is 24È36 h ;
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elimination is through the kidneys. In spite of its rather slow excretion, it appears
reasonable to give it at the beginning of meals and eventually before going to bed.
The drug is usually well tolerated and allergic reactions to the presently com-
mercially available preparation are rare.
Following diazoxide therapy, lactic acidaemia in both patients improved and in
patient 1 triglycerides and HDL-cholesterol levels nearly normalized. Although
there were no signiÐcant changes of plasma pH and in bicarbonate concentrations,
negative values of base excess ameliorated in both patients, suggesting a reduction
in acid load. The impressive increase of height velocity SDS came with a delay of
several months and without simultaneous advance in bone age. There was no indi-
cation that this initial increase was related to a pubertal growth spurt. Pubertal
maturation was delayed in both patients as usually seen in GSD Ia, but in the
meantime it has started in both girls.
The diminution of the liver size in both patients on diazoxide therapy was impres-
sive. Diazoxide may lessen fatty inÐltration of the liver and hyperlipidaemia through
indirect inhibition of peripheral lipolysis. Hyperlipidaemia results from
hypoglycaemia-induced lipolysis and increased triglyceride synthesis from plasma
free fatty acids in the liver.
We conclude from our observations that diazoxide prolonged the postprandial
euglycaemia, preventing early fasting hypoglycaemia. It successfully reduced lactic
acidosis and thereby induced the impressive catch-up-growth in our patients. Since
short stature is a psychological problem during childhood, we consider that diaz-
oxide may be an alternative add-on treatment, to allow a normal growth during this
period in patient with GSD type Ia.
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